Chunyan Yang

Dr. Chunyan Yang


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2022 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
BYBenqiang Yao
Benqiang Yao
CYChunyan Yang
Chunyan Yang
CPChengxi Pan
Chengxi Pan
YLYong Li
Yong Li

10 February 2022 in Environmental Pollution
Verified
Journal Article
Closed access
FRFengkai Ruan
Fengkai Ruan
CLChangqian Liu
Changqian Liu
WHWeiping Hu
Weiping Hu
JRJinpeng Ruan
Jinpeng Ruan
XDXiaoyan Ding
Xiaoyan Ding
JHJiyi Huang
Jiyi Huang

27 January 2014 in Marine Drugs
Verified
Journal Article
Open access
PDF file
CYChunyan Yang
Chunyan Yang
QLQianrong Li
Qianrong Li
YLYong Li
Yong Li
Nuclear receptors (NRs) are important pharmaceutical targets because they are key regulators of many metabolic and inflammatory diseases, including diabetes, dyslipidemia, cirrhosis, and fibrosis. As ligands play a pivotal role in modulating nuclear receptor activity, the discovery of novel ligands for nuclear receptors represents an interesting and promising therapeutic approach. The search for novel NR agonists and antagonists with enhanced selectivities prompted the exploration of the extraordinary chemical diversity associated with natural products. Recent studies involving nuclear receptors have disclosed a number of natural products as nuclear receptor ligands, serving to re-emphasize the translational possibilities of natural products in drug discovery. In this review, the natural ligands of nuclear receptors will be described with an emphasis on their mechanisms of action and their therapeutic potentials, as well as on strategies to determine potential marine natural products as nuclear receptor modulators.

19 January 2022 in Journal of Environmental Sciences
Verified
Journal Article
Closed access
CSChao Shen
Chao Shen
JHJing He
Jing He
KZKongyang Zhu
Kongyang Zhu
NZNaying Zheng
Naying Zheng
YYYue Yu
Yue Yu
Zhenghong ZuoZhenghong Zuo
Zhenghong Zuo

1 January 2022 in Life Sciences
Verified
Journal Article
Closed access
SRSongwen Ren
Songwen Ren
YGYou Gao
You Gao
LWLuanjin Wang
Luanjin Wang
CQCe Qiu
Ce Qiu
LYLingtao Yang
Lingtao Yang
He ChengyongHe Chengyong
He Chengyong

19 September 2016 in Scientific Reports
Verified
Journal Article
Open access
QWQun Wei
Qun Wei
HLHaiyan Liu
Haiyan Liu
MLMiao Liu
Miao Liu
CYChunyan Yang
Chunyan Yang
JYJie Yang
Jie Yang
PYPing Yang
Ping Yang
Prior studies have shown that overexpression of ACT A can lead to ventricular remodeling in rat models of heart failure. Furthermore, recently work studying demonstrated that stimulation of activin An expression in rat aortic smooth muscle (RASM) cells by angiotensin II (Ang II). Ramipril is a recently developed angiotensin converting enzyme (ACE) inhibitor. To investigate the effects of Ramipril on expression of ACT A-FS, we established the rat model of heart failure after myocardial infarction (MI), and divided into either a sham operation (SO), MI, or MI-Ramipril group. We found that Ramipril significantly attenuates collagen-I and III deposition (col-I and III). Notably, we determined that expression of ACT A and II activin receptor (ActRII) were significantly down-regulated in the non-infarcted area of the left ventricle in the Ramipril group, whereas the mRNA and protein levels of FS were markedly up-regulated. Our data suggested that Ramipril benefited left ventricular remodeling by reducing fibrosis and collagen accumulation in the left ventricle of rats after myocardial infarction. This observation was also associated with down-regulation of ACT A expression. This study elucidated a new protective mechanism of Ramipril and suggests a novel strategy for treatment of post-infarct remodeling and subsequent heart failure.